Global PDGFR Inhibitors Market Analysis, Application & Forecast to 2021-2026 (Business Opportunities - Other Business Ads)

UKAdsList > Business Opportunities > Other Business Ads

Item ID 8912165 in Category: Business Opportunities - Other Business Ads

Global PDGFR Inhibitors Market Analysis, Application & Forecast to 2021-2026

Bharat Book Bureau Provides the Trending Market Research Report on “Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026” under Life Sciences Market Research Reports Category. The report offers a collection of superior market research, market analysis, competitive intelligence and Market reports.

Global PDGFR Inhibitors Market Report Analysis & Data Highlights:

• Research Methodology
• Global & Regional Market Analysis
• Global PDGFR Inhibitors Market Opportunity Assessment: > USD 4 Billion
• Global PDGFR Inhibitors Market & Drug Sales Insight 2020 Till 2026
• Approved Drug In Market: 2 (Lartruvo & Ayvakit)
• Approved PGDFR Drug Patent, Price & Sales insight 2020 Till 2026
• Future market Assessment By Indication & Region Till 2026
• Ongoing Clinical Trials Assessment by Status, Phase & Region
• Global PDGFR Inhibitors Key Market Dynamics
• Global PDGFR Inhibitors Competitor Landscape

Platelet derived growth factor (PDGF) are the members of growth factor receptors which are found to be overexpressed in many cancers, correlating with reduced overall survival. In some cancer types, PDGF receptors are expressed on non-cancerous cells of the tumor microenvironment or tumor stroma that are able to crosstalk with cancer and thus have critical role in the development of cancer. Over the time, it has emerged out to be an important target for the drug therapies intended for treatment wide range of cancers.

Avapritinib sold under brand name Ayvakit is the first approved PDGFR inhibitor available in market. The drug was developed by Blueprint Medicines and is mainly indicated for the treatment of gastrointestinal tumors (GIST) and mastocytosis. The FDA approval of Ayvakit represents a major breakthrough in the treatment of rare GIST. Since it introduction into the market, the drug has shown high adoption rates among patients worldwide. The rise in prevalence of cancer and high medical needs for targeted therapy associated with increasing awareness regarding the availability of drug will further enhance its growth in market for next few years.

In the same year, Ripretinib sold under brand name Qinlcok has also gained approval. The drug is developed by Deciphera Pharmaceuticals and is indicated for the treatment of gastrointestinal tumors. In short span of time, the drug has shown robust sales in the global market. Owing to its high specificity towards PDGFR and ability to target broad spectrum of kinases, it is expected that the drug will dominate the overall PDGFR inhibitor market in coming years. Although the market is poised to growth in coming years but several factors limits their growth in market. The high cost of cancer therapy is one of the major limiting factors which will restrict the growth of market in coming years.

Related Link: Click here to visit item owner's website (0 hit)

Target Nation: All Nations
Target City : All Cities
Last Update : 21 October 2021 12:43 PM
Number of Views: 18
Item  Owner  : James Grey
Contact Email:
Contact Phone: 02227810772

Friendly reminder: Click here to read some tips.
UKAdsList > Business Opportunities > Other Business Ads
 © 2021
2021-12-05 (0.229 sec)